Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (245) 245
pd-1 (219) 219
pd‐1 (216) 216
humans (173) 173
immunotherapy (143) 143
cancer (117) 117
oncology (113) 113
t cells (113) 113
apoptosis (101) 101
female (98) 98
immunology (88) 88
lymphocytes (88) 88
male (85) 85
pd-l1 (81) 81
immune checkpoint (73) 73
pd‐l1 (73) 73
animals (72) 72
nivolumab (72) 72
lymphocytes t (68) 68
tumors (66) 66
middle aged (64) 64
analysis (60) 60
cell death (59) 59
adult (58) 58
expression (58) 58
aged (57) 57
melanoma (56) 56
patients (54) 54
care and treatment (52) 52
pembrolizumab (51) 51
ligands (50) 50
mice (50) 50
metastasis (44) 44
t-cells (44) 44
cell biology (42) 42
ipilimumab (42) 42
flow cytometry (41) 41
immune system (40) 40
blockade (39) 39
chemotherapy (38) 38
dendritic cells (38) 38
survival (38) 38
hematology (37) 37
programmed cell death 1 receptor - immunology (37) 37
clinical trials (36) 36
lung cancer (36) 36
activation (34) 34
immunohistochemistry (34) 34
pd-1 protein (34) 34
programmed cell death 1 receptor (34) 34
cd8 antigen (33) 33
cd8-positive t-lymphocytes - immunology (33) 33
ctla-4 (33) 33
medical research (33) 33
safety (33) 33
therapy (32) 32
antibodies (30) 30
antigens (30) 30
cytotoxicity (30) 30
programmed cell death 1 receptor - antagonists & inhibitors (30) 30
programmed cell death 1 receptor - metabolism (30) 30
metastases (29) 29
original (29) 29
prognosis (29) 29
ctla‐4 (28) 28
gene expression (28) 28
pathology (28) 28
programmed death-1 (27) 27
t-lymphocytes - immunology (27) 27
aged, 80 and over (26) 26
b7-h1 antigen (26) 26
health aspects (26) 26
immunity (26) 26
tolerance (26) 26
exhaustion (25) 25
immune response (24) 24
open-label (24) 24
antibodies, monoclonal - therapeutic use (23) 23
b7-h1 (23) 23
b7-h1 antigen - metabolism (23) 23
cancer therapies (23) 23
article (22) 22
b7 family (22) 22
biomarkers (22) 22
cd4 antigen (22) 22
drug therapy (22) 22
medical prognosis (22) 22
pd-l1 protein (22) 22
programmed cell death 1 receptor - genetics (22) 22
autoimmunity (21) 21
cytokines (21) 21
inhibitors (21) 21
mice, inbred c57bl (21) 21
up-regulation (21) 21
anti-pd-1 (20) 20
inflammation (20) 20
lymphocyte activation - immunology (20) 20
proteins (20) 20
surgery (20) 20
antigens, cd - metabolism (19) 19
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Adsorption of SF 6 decomposition components over Pd (1 1 1): A density functional theory study
by Liu, Daikun and Gui, Yingang and Ji, Chang and Tang, Chao and Zhou, Qu and Li, Jie and Zhang, Xiaoxing
Applied Surface Science, ISSN 0169-4332, 01/2019, Volume 465, pp. 172 - 179
This work studies the adsorption properties of Pd(1 1 1) surface to various SF decomposition components (H S, SO , SOF , and SO F ). Due to the affluent active... 
Surface adsorption | Pd(1 1 1) adsorbent | SF6 decomposition components | DFT calculations
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Associations of ICOS and PD.1 gene variants with colon cancer risk in the Iranian population
by Shamsdin, Seyedeh Azra and Karimi, Mohammad Hossein and Hosseini, Seyed Vahid and Geramizadeh, Bita and Fattahi, Mohamad Reza and Mehrabani, Davood and Moravej, Ali
Asian Pacific Journal of Cancer Prevention, ISSN 1513-7368, 03/2018, Volume 19, Issue 3, pp. 693 - 698
Background: Positive and negative co-stimulatory molecules are important factors determining the outcome of immune responses to the presence of tumors. Since... 
PD.1 | Colon cancer | ICOS | Polymorphism | polymorphism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text PD‐L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti‐PD‐1/PD‐L1 clinical trials
by Madore, Jason and Vilain, Ricardo E and Menzies, Alexander M and Kakavand, Hojabr and Wilmott, James S and Hyman, Jessica and Yearley, Jennifer H and Kefford, Richard F and Thompson, John F and Long, Georgina V and Hersey, Peter and Scolyer, Richard A
Pigment Cell & Melanoma Research, ISSN 1755-1471, 05/2015, Volume 28, Issue 3, pp. 245 - 253
Summary This study evaluated the expression of PD‐L1 in immunotherapy‐naïve metastatic melanoma patients to determine longitudinal intrapatient concordance and... 
pathology | metastasis | immunotherapy | diagnosis | melanoma | PD‐1 | biomarker | prognosis | heterogeneity | PD‐L1 | Heterogeneity | Pathology | Biomarker | Prognosis | Immunotherapy | Melanoma | PD-L1 | Diagnosis | Metastasis | PD-1 | SURVIVAL | INDEPENDENT PREDICTOR | SAFETY | ANTIBODY | CELL BIOLOGY | DERMATOLOGY | ONCOLOGY | UP-REGULATION | TUMOR MICROENVIRONMENT | Immunohistochemistry | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Humans | Middle Aged | Male | Clinical Trials as Topic | Melanoma - pathology | Genetic Heterogeneity | Skin Neoplasms - metabolism | B7-H1 Antigen - metabolism | Neoplasm Metastasis | Neoplasm Grading | Melanoma - immunology | Survival Analysis | Female | Lymphocytes, Tumor-Infiltrating - immunology | Clinical trials | Medical research | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The PD‐1 pathway in tolerance and autoimmunity
by Francisco, Loise M and Sage, Peter T and Sharpe, Arlene H
Immunological Reviews, ISSN 0105-2896, 07/2010, Volume 236, Issue 1, pp. 219 - 242
Regulatory T cells (Tregs) and the PD‐1: PD‐ligand (PD‐L) pathway are both critical to terminating immune responses. Elimination of either can result in the... 
regulatory T cells | PD‐1 | PD‐L2 | Foxp3 | PD‐L1 | PD-L1 | PD-L2 | Regulatory T cells | PD-1 | COLLAGEN-INDUCED ARTHRITIS | PROGRAMMED DEATH-1 PD-1 | IMMUNOLOGY | CHRONIC VIRAL-INFECTION | INDUCED UP-REGULATION | NONOBESE DIABETIC MICE | TRANSCRIPTION FACTOR FOXP3 | REGULATORY T-CELLS | CENTRAL-NERVOUS-SYSTEM | GASTRIC EPITHELIAL-CELLS | SCURFY MOUSE MUTANT | Antigens, CD - immunology | T-Lymphocytes, Regulatory - metabolism | Apoptosis Regulatory Proteins - immunology | B7-H1 Antigen | Humans | Autoimmune Diseases - immunology | Antigens, CD - metabolism | Apoptosis Regulatory Proteins - metabolism | T-Lymphocytes, Regulatory - immunology | Signal Transduction - immunology | Models, Immunological | Animals | Autoimmunity - immunology | Immune Tolerance - immunology | Programmed Cell Death 1 Receptor | Autoimmune Diseases - metabolism | Autoimmunity | T cells | Tregs
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text PD-1 and its ligands in tolerance and immunity
by Keir, Mary E and Butte, Manish J and Freeman, Gordon J and Sharpe, Arlene H
Annual Review of Immunology, ISSN 0732-0582, 2008, Volume 26, Issue 1, pp. 677 - 704
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that regulate the balance between T cell activation, tolerance, and... 
Autoimmunity | Infectious disease | Tumor | Costimulation | T cell | RESPONSES IN-VIVO | EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | DENDRITIC CELLS | CHRONIC HEPATITIS-B | IMMUNOLOGY | GAMMA-DEPENDENT MECHANISM | CROSS-LINKING ANTIBODY | costimulation | autoimmunity | infectious disease | tumor | PROGRAMMED DEATH-1 PATHWAY | T-CELL-ACTIVATION | GASTRIC EPITHELIAL-CELLS | Immunity - physiology | Models, Immunological | Animals | B7-H1 Antigen | Humans | B7-1 Antigen - physiology | Antigens, CD - physiology | Apoptosis Regulatory Proteins - physiology | Ligands | Programmed Cell Death 1 Receptor | Self Tolerance - physiology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy
by Zuazo, Miren and Arasanz, Hugo and Fernández-Hinojal, Gonzalo and García-Granda, Maria Jesus and Gato, María and Bocanegra, Ana and Martínez, Maite and Hernández, Berta and Teijeira, Lucía and Morilla, Idoia and Lecumberri, Maria Jose and Fernández de Lascoiti, Angela and Vera, Ruth and Kochan, Grazyna and Escors, David
EMBO molecular medicine, ISSN 1757-4676, 07/2019, Volume 11, Issue 7, p. e10293
The majority of lung cancer patients progressing from conventional therapies are refractory to PD-L1/PD-1 blockade monotherapy. Here, we show that baseline... 
lung cancer | Immunology | B7‐H1 | immunotherapy | biomarker | PD‐1 | PD‐L1 | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Programmed death‐1 inhibitor for occupational intrahepatic cholangiocarcinoma caused by chlorinated organic solvents
by Tanaka, Shogo and Kubo, Shoji
Journal of Hepato‐Biliary‐Pancreatic Sciences, ISSN 1868-6974, 06/2019, Volume 26, Issue 6, pp. 242 - 243
Highlight Tanaka and Kubo reported the first case of recurrent occupational cholangiocarcinoma treated with programmed death‐1 inhibitor. A programmed death‐1... 
Occupational cholangiocarcinoma | Programmed death‐ligand 1 | PD‐1 inhibitor | CA19‐9 | Nivolumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non‐Small Cell Lung Cancer With Progression On or After Platinum‐Based Chemotherapy
by Kazandjian, Dickran and Suzman, Daniel L and Blumenthal, Gideon and Mushti, Sirisha and He, Kun and Libeg, Meredith and Keegan, Patricia and Pazdur, Richard
The Oncologist, ISSN 1083-7159, 05/2016, Volume 21, Issue 5, pp. 634 - 642
On October 9, 2015, the U.S. Food and Drug Administration expanded the nivolumab metastatic non‐small cell lung cancer (NSCLC) indication to include patients... 
Non‐small cell lung carcinoma | PD‐1 inhibitor | Nivolumab | Immunotherapy | Non-small cell lung carcinoma | PD-1 inhibitor | TRIAL | ONCOLOGY | BLOCKADE | DOCETAXEL | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | United States | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Drug Approval | Carcinoma, Non-Small-Cell Lung - mortality | Disease Progression | Taxoids - therapeutic use | Neoplasm Metastasis | Aged, 80 and over | Adult | Female | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | United States Food and Drug Administration | FDA | Regulatory Issues
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Molecular predictors in immune oncology
by Weichert, W
Pathologe, ISSN 0172-8113, 11/2018, Volume 39, Issue 6, pp. 546 - 555
Molecular diagnostics | DNA damage response | PD-L1 | PD‑1 | Microbiome
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Role of the PD‐1 Pathway in the Immune Response
by Riella, L. V and Paterson, A. M and Sharpe, A. H and Chandraker, A
American Journal of Transplantation, ISSN 1600-6135, 10/2012, Volume 12, Issue 10, pp. 2575 - 2587
Understanding immunoregulatory mechanisms is essential for the development of novel interventions to improve long‐term allograft survival. Programmed death 1... 
regulatory T cells | costimulation | transplantation | PD‐1 | PD‐L2 | tolerance | Alloimmunity | PD‐L1 | PD-L1 | PD-L2 | PD-1 | SURGERY | FOXP3 EXPRESSION | ALLOGRAFT-REJECTION | DENDRITIC CELLS | PROGRAMMED DEATH LIGAND-1 | TISSUE EXPRESSION | CUTTING EDGE | POSITIVE SELECTION | COSTIMULATORY PATHWAYS | REGULATORY T-CELLS | ANTIBODY-RESPONSES | Signal Transduction | Lymphocyte Activation | Humans | Immune Tolerance | Programmed Cell Death 1 Receptor - metabolism | Graft Survival | Organ Transplantation | Programmed Cell Death 1 Receptor - physiology | T-Lymphocytes, Regulatory - immunology | T cells | Analysis | alloimmunity
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
by González‐Martín, Antonio and Sánchez‐Lorenzo, Luisa
Cancer, ISSN 0008-543X, 12/2019, Volume 125, Issue S24, pp. 4616 - 4622
Despite advances in surgery and chemotherapy and the integration of antivascular endothelial growth factor therapy as well as poly(adenosine... 
immunotherapy combinations | antiprogrammed cell death protein 1 (anti‐PD‐1) | ovarian cancer | immunotherapy | antiprogrammed death‐ligand 1 (anti‐PD‐L1) | checkpoint inhibitor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE‐013
by Ribrag, Vincent and Avigan, David E and Green, Damian J and Wise‐Draper, Trisha and Posada, Juan G and Vij, Ravi and Zhu, Ying and Farooqui, Mohammed Z. H and Marinello, Patricia and Siegel, David S
British Journal of Haematology, ISSN 0007-1048, 08/2019, Volume 186, Issue 3, pp. e41 - e44
pembrolizumab | PD‐1 (PDCD1) | multiple myeloma | PD-1 (PDCD1) | DARATUMUMAB | DEXAMETHASONE | HEMATOLOGY | Medicine, Experimental | Medical research | Multiple myeloma | Refractory materials | Pembrolizumab
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Treatment de‐escalation in HPV‐positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives
by Mirghani, H and Amen, F and Blanchard, P and Moreau, F and Guigay, J and Hartl, D.M and Lacau St Guily, J
International Journal of Cancer, ISSN 0020-7136, 04/2015, Volume 136, Issue 7, pp. 1494 - 1503
Due to the generally poor prognosis of head and neck squamous cell carcinoma (HNSCC), treatment has been intensified, these last decades, leading to an... 
PD‐1:PD‐L1 immune checkpoint | PI3K pathway | oropharyngeal cancers | human papillomavirus | treatment de‐escalation | Oropharyngeal cancers | Treatment de-escalation | Human papillomavirus | PD-1:PD-L1 immune checkpoint | SQUAMOUS-CELL-CARCINOMA | GYNECOLOGIC-ONCOLOGY-GROUP | INDUCTION CHEMOTHERAPY | treatment de-escalation | ROBOTIC SURGERY | HUMAN-PAPILLOMAVIRUS | INTRAEPITHELIAL NEOPLASIA | CANCER | PHASE-II TRIAL | ONCOLOGY | LOCALLY ADVANCED HEAD | SELECTIVE NECK DISSECTION | Oropharyngeal Neoplasms - therapy | Cancer Vaccines - therapeutic use | Papillomavirus Infections - complications | Humans | Oropharyngeal Neoplasms - etiology | Treatment Outcome | Clinical Trials as Topic | Combined Modality Therapy | Clinical trials | Papillomavirus infections | Squamous cell carcinoma | Laryngeal cancer | Cancer therapies | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Use of PD‐1 (PDCD1) inhibitors for the treatment of Richter syndrome: experience at a single academic centre
by Rogers, Kerry A and Huang, Ying and Dotson, Emily and Lundberg, Jordan and Andritsos, Leslie A and Awan, Farrukh T and Woyach, Jennifer A and Byrd, John C
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 2, pp. 363 - 366
PD‐1 (PDCD1) inhibitors | chronic lymphocytic leukaemia | Richter syndrome | immune checkpoint inhibitors | PD-1 (PDCD1) inhibitors | HEMATOLOGY | CHEMOIMMUNOTHERAPY | Care and treatment | Usage | Leukemia
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text PD‐1 is highly expressed by neoplastic B‐cells in Richter transformation
by Behdad, Amir and Griffin, Brannan and Chen, Yi‐Hua and Ma, Shuo and Kelemen, Katalin and Lu, Xinyan and Chen, Qing C
British Journal of Haematology, ISSN 0007-1048, 04/2019, Volume 185, Issue 2, pp. 370 - 373
PD‐L1 (CD274) | chronic lymphocytic leukaemia | Richter syndrome | PD‐1 (PDCD1) | PD-1 (PDCD1) | PD-L1 (CD274) | HEMATOLOGY | Antimitotic agents | Antineoplastic agents | Leukemia | Lymphocytes B | Transformation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Assessment by miRNA microarray of an autologous cancer antigen‐pulsed adoptive immune ensemble cell therapy (AC‐ACT) approach; demonstrated induction of anti‐oncogenic and anti‐PD‐L1 miRNAs
by Chinami, Masanobu and Iwabuchi, Kaoru and Muto, Yoshiteru and Uchida, Yasuhiko and Arita, Ryu and Shuraim, Rana A and Adra, Chaker N
Clinical Case Reports, ISSN 2050-0904, 11/2019, Volume 7, Issue 11, pp. 2156 - 2164
A 60‐year‐old woman with stage IV rectal cancer received adoptive cell therapy with autologous cancer antigen (AC‐ACT) causing induction of anti‐oncogenic and... 
cancer | PD‐1 | adoptive cell therapy | miRNA analysis | immunotherapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights